ArticleeLife2021
Enrichment of
Open access · goldAbstract read
In one paragraph
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 81 citations in OpenAlex.
- Nicotinamide Mononucleotide Adenylyltransferase 1 and NADMetabolites · 2026Review
- Review
- Boldine inhibits SARM1 NADase Activity and Preserves Axonal Integrity After Nerve Injury.bioRxiv : the preprint server for biology · 2026Article
- SARM1 activation promotes axonal degeneration via a two-step phase transition.Nature chemical biology · 2026Article
- Programmed axon degeneration: mechanism, inhibition and therapeutic potential.Nature reviews. Neuroscience · 2026Review
- A CRISPR activation screen reveals a cilia disassembly pathway mutated in focal cortical dysplasia.Science advances · 2025Article
- Transcriptome-based screening in TARDBP/TDP-43 knock-in motor neurons identifies the NEDD8-activating enzyme inhibitor MLN4924.Scientific reports · 2025Article
- Pyruvate kinase deficiency links metabolic perturbations to neurodegeneration and axonal protection.Molecular metabolism · 2025Article
- SARM1: The Checkpoint of Axonal Degeneration in the Nervous System Disorders.Molecular neurobiology · 2025Review
- Suppressing phagocyte activation by overexpressing the phosphatidylserine lipase ABHD12 preserves sarmopathic nerves.iScience · 2025Article
- TIR immune signalling is blocked by phosphorylation to maintain plant growth.Nature plants · 2025Article
- Genetic Ablation of Sarm1 Mitigates Disease Acceleration after Traumatic Brain Injury in the SOD1Annals of neurology · 2025Article
- SARM1: a key multifaceted component in immunoregulation, inflammation and neurodegeneration.Frontiers in immunology · 2025Review
- Review
- Review
- SARM1-Dependent Axon Degeneration: Nucleotide Signaling, Neurodegenerative Disorders, Toxicity, and Therapeutic Opportunities.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2024Review
- Programmed axon death: a promising target for treating retinal and optic nerve disorders.Eye (London, England) · 2024Review
- Brain energy metabolism: A roadmap for future research.Journal of neurochemistry · 2024Review
- Dietary NMN supplementation enhances motor and NMJ function in ALS.Experimental neurology · 2024Article
- Abnormal Brain Protein Abundance and Cross-tissue mRNA Expression in Amyotrophic Lateral Sclerosis.Molecular neurobiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 11 institutions in 7 countries.
Jonathan GilleyJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-9510-7956
Oscar JacksonJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-1825-9331
Menelaos PipisDepartment of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology, London, United Kingdom.
Mehrdad A EstiarDepartment of Human Genetics, McGill University, Montreal, Canada.
Ammar Al-ChalabiDepartment of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Matt C DanziDr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, United States.
Kristel R van EijkDepartment of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Stephen A GoutmanDepartment of Neurology, University of Michigan, Ann Arbor, United States.
Matthew B HarmsInstitute for Genomic Medicine, Columbia University, New York, United States.
Henry HouldenDepartment of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology, London, United Kingdom.
Alfredo IacoangeliDepartment of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Julia KayeCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, United States.
Leandro LimaCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, United States.
Queen Square GenomicsDepartment of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology, London, United Kingdom.
John RavitsDepartment of Neurosciences, University of California, San Diego, La Jolla, United States.
Guy A RouleauDepartment of Human Genetics, McGill University, Montreal, Canada.
Rebecca SchüleCenter for Neurology and Hertie Institute für Clinical Brain Research, University of Tübingen, German Center for Neurodegenerative Diseases, Tübingen, Germany.
Jishu XuCenter for Neurology and Hertie Institute für Clinical Brain Research, University of Tübingen, German Center for Neurodegenerative Diseases, Tübingen, Germany.
Stephan ZüchnerDr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, United States.
Johnathan Cooper-KnockSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, United Kingdom.
Ziv Gan-OrDepartment of Human Genetics, McGill University, Montreal, Canada.
Mary M ReillyDepartment of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology, London, United Kingdom.
Michael P ColemanJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
Montreal Neurological Institute and Hospital · CAUniversity of Cambridge · GBDr. John T. Macdonald Foundation · USGerman Center for Neurodegenerative Diseases · DEGladstone Institutes · USKing's College London · GBNational Hospital for Neurology and Neurosurgery · GBCenter for Genomic Science · ITUniversity of California San Diego · USUniversity of Michigan · USUtrecht University · NL
Funding
trainingU54NS065712 · NINDS · WAYNE STATE UNIVERSITY · PI SHY, MICHAEL E. · 2009 to 2023
$19.6MGENOME STUDIES IN HEREDITARY SPASTIC PARAPLEGIA - beyond the exomeR01NS072248 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Stephan Zuchner · 2011 to 2026
$9.2MGenomic Studies in Charcot-Marie-Tooth DiseaseR01NS105755 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SHY, MICHAEL E., ZUCHNER, STEPHAN · 2019 to 2023
$3.2MImpact of Geospatial Factors and Environmental Pollutants on Amyotrophic Lateral Sclerosis in the State of MichiganK23ES027221 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GOUTMAN, STEPHEN · 2017 to 2021
$1.0MBiotechnology and Biological Sciences Research Council BB/S009582/1Medical Research Council MR/L501529/1Medical Research Council MR/N004582/1Medical Research Council MR/R024804/1National Institutes of Neurological Diseases and Stroke and office of Rare Diseases U54NS065712NIEHS NIH HHS K23 ES027221NINDS NIH HHS R01 NS072248NINDS NIH HHS R01 NS105755NINDS NIH HHS U54 NS065712Wellcome TrustWellcome Trust 216596/Z/19/ZWellcome Trust 220906/Z/20/Z
Abstract
SARM1, a protein with critical NADase activity, is a central executioner in a conserved programme of axon degeneration. We report seven rare missense or in-frame microdeletion human
Indexed as
AdultAgedAllelesAmyotrophic Lateral SclerosisAnimalsArmadillo Domain ProteinsCytoskeletal ProteinsFemaleHumansMaleMiceMiddle AgedMotor Neuron DiseaseNAD+ NucleosidaseNicotinamide MononucleotideArmadillo Domain ProteinsCytoskeletal ProteinsNAD+ NucleosidaseNicotinamide MononucleotideSARM1 protein, humanALSgeneticsgenomicshumanNADaseneurosciencerisk alleleSARM1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.